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LETTER TO THE EDITOR
Prophylactic octreotide in pancreatoduodenectomy: response to
Yang et al.
We appreciate the comments of Yang and colleagues on our
recent work entitled ‘Prophylactic octreotide for pancreatoduo-
denectomy: more harm than good?’1 We agree with several of their
points, particularly that the current evidence in the translational
literature directly linking octreotide to the formation of fistulas is
far from definitive; however, defining the mechanism of fistula
development in the setting of prophylactic octreotide was beyond
the scope of our paper. Despite this, we cited over 15 studies that
may explain our clinical findings.
Secondly, although our findings contrast with those of several
randomized controlled trials (RCTs), each of those studies pre-
dated the advent of the International Study Group on Pancreatic
Fistula,2 which established definitions for clinically relevant post-
operative pancreatic fistula (CR-POPF) through international
consensus. In fact, although the differences were non-significant,
the only RCTs to be conducted since those definitions were pub-
lished have reported higher rates of fistula formation with
octreotide.3,4 The overall fistula rates in our study (octreotide
group: 28.1%; control group: 21.5%) compare favourably with
those in the most recent RCT (octreotide group: 25%; control
group: 18%).4 Contrasting findings were recently reported with
the new somatostatin analogue, pasireotide, but the efficacy of this
drug has not been tested in a multicentre fashion.5
Lastly, a forthcoming study by our group of outcomes in over
4300 pancreatoduodenectomies performed by 55 surgeons at 15
institutions found octreotide to be associated with a greater inci-
dence of CR-POPF [odds ratio (OR) 3.3; P < 0.0001] similar to the
figures reported in our recent paper (OR 2.6; P < 0.001).1 The later
study controlled for elements of endogenous and operative risk, as
well as for mitigation strategies (octreotide, drains, stents, etc.),
institutional volume and surgeon experience. An important
takeaway from that analysis, and our paper on octreotide,1 is that
fistula risk is multifactorial; octreotide was associated with
elevated CR-POPF rates, but other factors also rose to statistical
significance. We believe it is imperative to control for all compo-
nents of CR-POPF risk when evaluating the efficacy of fistula
mitigation strategies.
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